We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Croatian generic drugmaker Pliva,
at the centre of a bid battle, said on Friday U.S. regulators had given a green
light to three of its drugs after problems were fixed at production facilities
in Zagreb.
BioSpace (http://www.biospace.com/news_story.aspx?StoryId=23611)
